Key result
VKA therapy carries a ~13% bleeding prevalence, linked to advanced age and poor adherence.
Why the study?
What are the frequency and risk factors for bleeding and asymptomatic overdose in patients on Vitamin K antagonist therapy?
Cross-Sectional (n=111)
No
What are the frequency and risk factors for bleeding and asymptomatic overdose in patients on Vitamin K antagonist therapy?
Lack of patient education and information are major contributors to bleeding and overdose risks in patients taking Vitamin K antagonists, highlighting the need for therapeutic education programs.
Bleeding and overdose rates in VKA users warrant caution with elderly or nonadherent patients; leaves open prospective trials of education programs.
BACKGROUND: Vitamin K antagonists are widely used in the treatment and prevention of thromboembolic disease. However, these drugs can cause serious side effects, especially bleeding. This study aims to evaluate frequency and risk factors of both bleeding and asymptomatic overdose in North African patients undergoing Vitamin K antagonist therapy. METHODS: We performed a cross-sectional study in patients undergoing Vitamin K antagonist therapy. A statistical analysis has been conducted to identify overdose and bleeding risk factors by using chi-square test (p < .05). RESULTS: One hundred and eleven patients were included. We recorded 14 cases of bleeding and 26 cases of asymptomatic overdose. Advanced age, poor adherence, concomitant use of paracetamol and history of previous bleeding are significant risk factors of over-anticoagulation. An INR value over 6 at admission, a high therapeutic target range for INR, concomitant use of acetylsalicylic acid, lack of information on overdose signs and measures to be taken in case of bleeding were identified as risk factors for bleeding. CONCLUSION: Most of the risk factors identified in our study seem to be related to patients lack of information and education. These results highlight the importance of creating a therapeutic patient education program.
No takes yet. Share an insight, caveat, or question.
Mbarka et al. (2018) conducted a cross-sectional in Patients undergoing Vitamin K antagonist therapy (n=111). Vitamin K antagonist therapy was evaluated on Frequency of bleeding and asymptomatic overdose. In patients undergoing Vitamin K antagonist therapy, the prevalence of bleeding was 12.6% and asymptomatic overdose was 23.4%, with advanced age and poor adherence identified as significant risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: